01OverviewDefinition, clinical context and the essential points that orientate the chapter.
Invasive carcinoma of no special type is the commonest invasive epithelial breast malignancy. It is diagnosed when malignant epithelial cells extend beyond the duct-lobular basement membrane into stroma without a defining special morphology. Desmoplastic reaction produces firmness and architectural distortion. Grade describes tubule formation, nuclear pleomorphism and mitotic activity; it is distinct from anatomical stage, which describes tumour size, regional nodes and distant spread.
Invasive lobular carcinoma arises from terminal duct-lobular units and commonly loses E-cadherin-mediated cohesion. Its cells may spread as thin single-file cords through breast tissue with less desmoplasia than a mass-forming carcinoma. Clinical examination, mammography and ultrasound can therefore underestimate size or multifocality. This does not make MRI automatic: NICE reserves MRI for selected cases, while the RCR identifies lobular cancer being considered for breast conservation as a situation where defining extent may change a feasible operation.
Key points
- Invasive breast carcinoma has crossed the basement membrane and can enter lymphatic or blood vessels; “no special type” replaces the older default label invasive ductal carcinoma.
- Invasive carcinoma of no special type often forms a stellate mass, whereas lobular carcinoma more often infiltrates in single-file strands because loss of cell cohesion can obscure its true extent.
- Diagnosis needs concordant clinical assessment, age-appropriate bilateral imaging and image-guided core biopsy; record tumour type, grade and ER, PR and HER2 status.
- Use axillary ultrasound before treatment and sample abnormal nodes. A normal ultrasound or negative node sample usually leads to sentinel-node biopsy rather than immediate clearance at surgery.
- Preoperative MRI is not routine for every invasive cancer; consider it when conventional imaging does not define extent, breast density prevents reliable sizing, or lobular disease is being considered for breast conservation.
- Treatment combines local control and biology-directed systemic therapy. Surgical extent follows tumour distribution and patient preference, not the word ductal or lobular alone.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Accumulated somatic change
Genomic and epigenetic alterations permit luminal epithelial cells to proliferate, evade growth control and survive outside their native compartment.
Inherited susceptibility
A minority arise on a constitutional cancer-predisposition background, while most reflect age, hormonal exposure, environment and acquired cellular change.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Basement-membrane breach
Malignant epithelial cells cross the duct-lobular basement membrane into stroma, creating access to lymphatic and vascular channels.
- 2Desmoplastic invasion
No-special-type carcinoma often stimulates fibrous stromal reaction, producing a hard irregular mass and radiological spiculation or distortion.
- 3Loss of cellular cohesion
Lobular carcinoma commonly loses E-cadherin function, allowing discohesive cells to infiltrate in single-file strands with deceptively subtle imaging boundaries.
- 4Regional and distant spread
Tumour cells can reach axillary nodes and later bone, liver, lung or brain; stage records this distribution rather than microscopic type.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
A new irregular firm lesion, tethering, distortion or pathological nipple change suggests invasive disease but cannot establish histological subtype clinically.
Lobular carcinoma may present as vague thickening, asymmetry or architectural change rather than a discrete lump, and can be multifocal or bilateral.
Hard, rounded or morphologically abnormal axillary nodes raise suspicion of metastasis; supraclavicular disease changes regional stage and treatment planning.
ER, PR and HER2 results predict useful treatment pathways and must be interpreted with grade, proliferation, size, nodes and the patient’s overall health.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Image-guided core biopsyFirst step - Why
- Confirm invasion and provide sufficient tissue for type, grade and receptor testing.
- Interpretation and limitations
- A core showing stromal invasion distinguishes invasive carcinoma from in-situ disease. Correlate the sampled target with imaging; benign or insufficient tissue cannot close a discordant suspicious assessment.
- 02
Bilateral mammography and targeted ultrasound - Why
- Measure the index lesion, assess other breast tissue and define an imaging target.
- Interpretation and limitations
- Spiculation, distortion or an irregular hypoechoic mass supports malignancy. The apparent boundary may underestimate infiltrative lobular growth, so radiological-pathological concordance matters.
- 03
Axillary ultrasound with needle sampling - Why
- Identify and sample morphologically abnormal regional nodes before treatment.
- Interpretation and limitations
- A positive sample establishes nodal involvement for planning. Normal ultrasound or a negative adequately targeted sample does not eliminate microscopic disease and usually preserves a sentinel-node route.
- 04
Selected contrast-enhanced breast MRI - Why
- Clarify extent when conventional imaging is discordant or inadequate and the result could change breast-conserving surgery.
- Interpretation and limitations
- Additional enhancement needs targeted correlation and biopsy where feasible before a larger operation. MRI is sensitive but enhancement is not synonymous with malignancy.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Ductal carcinoma in situ
Atypical malignant epithelial cells remain confined by the basement membrane; core sampling may still underestimate an invasive component.
Radial scar or sclerosing lesion
Benign sclerosis can produce distortion and spiculation that mimic invasive carcinoma, requiring representative tissue and concordance.
Breast lymphoma
Lymphoid malignancy can cause a breast mass or nodes but has different histology, staging and systemic treatment from epithelial carcinoma.
Metastasis to breast
A non-breast primary can rarely seed breast tissue; morphology, immunophenotype and prior cancer history distinguish its origin.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01New invasive cancer pathwayBuild a concordant pretreatment mapFirst stepCore biopsy from a 24 mm lesion confirms grade 2 invasive lobular carcinoma and the patient hopes to conserve the breast.+
- 1Confirm that the core sampled the clinical and imaging target; request ER, PR and HER2 together and review grade and any lymphovascular invasion.
- 2Perform pretreatment axillary ultrasound and image-guided sampling of any abnormal node, documenting whether nodal disease is proven or only suspected.
- 3Compare examination, mammography and ultrasound measurements; because lobular histology and breast conservation make extent consequential, discuss selected MRI at the multidisciplinary meeting.
- 4Target and sample any MRI-only focus that would convert conservation to mastectomy rather than treating enhancement as a second cancer automatically.
- 5Agree breast and axillary surgery with the patient after reviewing tumour distribution, breast-to-tumour ratio, systemic strategy and reconstruction options; record the final concordant plan.
02Operable node-negative pathwayLimit axillary morbidity while stagingA small invasive carcinoma has a normal axillary ultrasound and no indication for neoadjuvant treatment.+
- 1Confirm operability, receptor status and whether breast conservation can achieve an acceptable oncological and cosmetic result.
- 2Offer sentinel lymph-node biopsy rather than axillary clearance for surgical staging, using the validated local dual-tracer pathway.
- 3Base adjuvant radiotherapy and systemic recommendations on final size, grade, margins, node burden and tumour biology at postoperative multidisciplinary review.
- 4Explain lymphoedema and sensory risks before axillary surgery and provide a route for early postoperative assessment.
03Discordant extent pathwayResolve the discrepancy before surgeryExamination suggests a 5 cm area of thickening but ultrasound reports a single 18 mm lesion and core confirms lobular carcinoma.+
- 1Ask radiology and pathology to confirm target identity and review the full mammographic pattern rather than accepting the smallest measurement.
- 2Use selected MRI if conventional imaging cannot define extent and a reliable answer will change the operation.
- 3Biopsy a separate management-changing focus and repeat sampling of any discordant target, then re-discuss the complete map at the multidisciplinary meeting.
- 4Share both breast-conserving and mastectomy options only after extent is established, making clear that histological subtype alone does not dictate mastectomy.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Lymph-node metastasis
Regional nodal involvement changes stage, radiotherapy fields and systemic planning and may cause later arm lymphoedema after treatment.
Distant recurrence
Haematogenous spread most often involves bone, liver, lung or brain and changes treatment from curative local therapy to systemic disease control.
Local recurrence
Residual microscopic disease or adverse tumour biology can lead to ipsilateral breast, chest-wall or regional recurrence after initial treatment.
Treatment morbidity
Surgery, radiotherapy and systemic therapy may produce pain, altered body image, lymphoedema, menopausal symptoms, cardiac toxicity or neuropathy.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- After core diagnosis, track completion and concordance of ER, PR, HER2, axillary assessment and the agreed staging investigations before definitive treatment.
- Following breast-conserving surgery, review radial margins and final invasive and in-situ extent; tumour at ink requires further surgery under NICE guidance.
- After axillary surgery, assess wound, shoulder movement, neuropathic symptoms, seroma and early arm swelling, with prompt lymphoedema advice when needed.
- Once treatment ends, use the specialist follow-up plan, including annual mammography for five years under NICE and ongoing symptom-triggered review rather than routine whole-body imaging.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
Type is not stage
Lobular and no-special-type labels describe morphology. Prognosis and treatment also depend on anatomical stage, grade, receptors, comorbidity and response.
E-cadherin aids classification
Loss of membranous E-cadherin supports lobular differentiation in the correct morphology, but pathology integrates the stain with architecture rather than using it alone.
MRI must answer a decision
The useful MRI is one requested for a defined uncertainty whose result can alter a realistic operation, followed by verification of additional targets.
Concordance prevents false reassurance
A benign or non-invasive core is unsafe when it does not explain a hard lesion or suspicious image; the discrepancy itself is a reason for reassessment.
11Common pitfallsFrequent interpretation and management errors.
- 01
Calling every invasive adenocarcinoma “ductal” obscures the current no-special-type terminology and may hide a lobular growth pattern relevant to extent.
- 02
Choosing mastectomy solely because the report says lobular ignores whether complete breast conservation is technically and oncologically feasible.
- 03
Ordering routine MRI for every biopsy-proven cancer creates incidental findings and delay without a defined management question.
- 04
Performing axillary clearance in a clinically and ultrasound node-negative patient bypasses the lower-morbidity sentinel-node staging route.